Lefosse advise Teleflex on the acquisition of BIOTRONIK

Lefosse acted alongside Goodwin Procter LLC as Brazilian counsel of Teleflex Incorporated on the acquisition of substantially all of the vascular intervention business of BIOTRONIK SE & Co. KG. for an estimated cash payment on closing of approximately €760 million, subject to certain adjustments as provided in the purchase agreement, including certain working capital and other customary adjustments.

The acquisition reflects Teleflex’s commitment to investing in the estimated USD 10 billion interventional cardiology and peripheral vascular market served by the company’s portfolio post close.

The acquired business will expand the Teleflex Interventional portfolio to include a broad suite of vascular intervention devices such as drug-coated balloons, drug-eluting stents, covered stents, balloon and self-expanding bare metal stents, and balloon catheters. The acquisition is subject to customary closing conditions, including receipt of certain regulatory approvals, and is expected to be completed by the end of the third quarter of 2025.

Lefosse advised in the Brazilian law aspects of the transaction and relied on partners Rubens Granja, Laura Affonso, Aloizio Lima, Marcelo Ribeiro and Gustavo Paes (pictured from left to right); associates Lucas Queiroz, Giulia Caruso, Gabriel Queiroz.

Goodwin Procter LLC relied on Rob Masella Masella, Amanda Gill, Markus Käpplinger, Adam Bellack,
Jean A. Lee, Wei Xu, William Stanton, Ben Colao, Kelvin Tsz Ho Chan and Stephanie Barbanell.